Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer

Inclusion Criteria: * Participants must have histologically or cytologically confirmed recurrent epithelial ovarian cancer. Eligible histologies include high grade serous, high grade endometrioid and clear cell ovarian carcinoma. * Participants must have measurable cancer defined by RECIST 1.1 criteria. * Patients must have received at least 1 lines of prior systemic therapy and be deemed platinum resistant/intolerant by their treating oncologist. Patients with germline or somatic BRCA1 or BRCA2 mutations must have received prior PARP inhibitor therapy as maintenance or treatment. Prior receipt of immune checkpoint blockade is allowed if grade 3 or higher toxicities were not experienced. * Age ≥18 years and \<85 years old. * ECOG performance status of 0 or 1. * Participants must meet the following organ and marrow function as defined below: * Absolute neutrophil count ≥1,000/mcL * Platelets ≥75,000/mcL * AST(SGOT)/ALT(SGPT) ≤3 x institutional ULN * Total bilirubin ≤1.5 x institutional upper limit of normal (ULN) (except Gilbert's or disease-related hemolysis, then \< 3 x ULN) * Serum creatinine ≤ 2.0 mg/dL OR glomerular filtration rate (GFR) ≥40 mL/min/1.73 m2 * Oxygen saturation: ≥ 90% on room air * Left ventricular ejection fraction (cardiac function) ≥ 40% * No laboratory evidence of ongoing hemolysis in opinion of investigator * Participants with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere …